論文・技術情報追加のお知らせ

1. A systematic safety assessment of zuranolone: real-world adverse event analysis from the FAERS database.

ズラノロンの副作用を大規模解析。神経・精神症状の監視が重要。

対象DB：FAERS

2. Drug-related suicidal events in children and teenagers: Age-stratified insights from FAERS.

若年層の薬剤性自殺を解析。薬剤や性別・年齢による死亡リスク差。

対象DB：FAERS

3. Vaccine-associated lupus and related organ involvements: A pharmacovigilance analysis of VAERS database 1990-2025.

ワクチン後のSLE発症を解析。HPV/HBVワクチンで強い関連。

対象DB：FAERS,VAERS

4. Cardiovascular Adverse Events of JAK vs. TNF Inhibitors using the Korean Pharmacovigilance Database.

JAK阻害薬はTNF阻害薬より血栓等の心血管リスクが高い可能性。

対象DB：FAERS,KAERS

5. Evaluation of Dexmedetomidine-Associated Bradycardia and Related Drug-Drug Interactions Using Electronic Health Record (EHR) and miRNA Target Analysis.

デクスメデトミジンの徐脈リスクを解析。高齢者や特定薬との併用。

対象DB：FAERS

6. Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab - a decade of FAERS pharmacovigilance.

ベドリズマブの消化管有害事象

対象DB：FAERS

7. Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

トロフィネチド実臨床有害事象の薬剤監視解析

対象DB：FAERS

8. Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study.

サトラリズマブ市販後安全性のFAERS/JADER解析

対象DB：FAERS,JADER

9. Exploring adverse events associated with vosoritide monotherapy: Insights from the FDA Adverse Event Reporting System.

ボソリチドの小児実臨床安全性

対象DB：FAERS

10. Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database.

タルラタマブ市販後安全性

対象DB：FAERS

11. Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease.

抗がん薬関連ILDの高リスク薬とCD40機序解明

対象DB：FAERS

12. Electronic Health Record Intervention and Deprescribing for Older Adults: A Randomized Clinical Trial.

行動科学EHR介入で高齢者不適切薬の減薬促進

対象DB：FAERS

13. Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring.

ダビガトランとキノロン併用で出血リスク増

対象DB：FAERS

14. Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System.

腸閉塞と関連する薬剤の大規模薬剤疫学解析

対象DB：FAERS

15. Pancreatitis induced by Peg-aspargase in children: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).

小児ALLにおけるペガスパルガーゼ安全性解析

対象DB：FAERS

16. Real-world adverse event profile and signal characteristics of bevacizumab in glioma: a FAERS-based disproportionality analysis.

ベバシズマブ膠芽腫の実世界安全性解析：血管・腎毒性と性差年齢差

対象DB：FAERS

17. Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.

ゲパン系CGRP拮抗薬の実世界安全性解析

対象DB：FAERS

18. Profiling of Potential Postmarket Risk Tracking and Pharmacovigilance Data for Avacopan.

アバコパン市販後安全性の実世界解析

対象DB：FAERS

19. Real-world database evaluation of drug-associated vitreous opacities and machine learning for clinical interpretability.

硝子体混濁に関連する薬剤リスクの実世界解析

対象DB：FAERS

20. Real-world safety profile of roflumilast: a pharmacovigilance analysis using FDA adverse event reporting system and Canada vigilance database.

ロフルミラストの実臨床有害事象解析

対象DB：CVAR,FAERS

21. Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database.

成人円形脱毛症におけるJAK阻害薬安全性比較解析

対象DB：FAERS

22. Real-world safety profile and mechanistic insights into regorafenib-induced liver failure: a pharmacovigilance study integrated with network toxicology.

レゴラフェニブ関連肝毒性の実臨床安全性解析

対象DB：FAERS

23. Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis.

サシツズマブ関連好中球減少症の安全性評価

対象DB：FAERS

24. Vancomycin is a risk factor for acute pancreatitis and increases the mortality rate in patients with severe pancreatitis.

重症膵炎におけるバンコマイシン予後影響と媒介因子解析の検討

対象DB：FAERS

25. Hepatobiliary disorders associated with TNF-alpha inhibitors: a pharmacovigilance analysis of FAERS and JADER.

TNFα阻害薬の肝胆道系安全性比較

対象DB：FAERS,JADER

26. Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems.

GLP-1作動薬の消化管・腎・膵安全性解析

対象DB：FAERS

27. Efficacy and Safety of Newly Diagnosed Multiple Myeloma Combination Therapies: A Systematic Review Integrating Network Meta-Analysis and Real-World Vigilance Study.

抗CD38併用療法の有効性と安全性解析

対象DB：FAERS

28. A Noisy Signal? Geographic Bias in FAERS Reports Linking Paracetamol to Autism Spectrum Disorder.

妊娠中アセトアミノフェンと自閉症報告の薬剤疫学解析

対象DB：FAERS

29. Drug-associated deep vein thrombosis: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database.

薬剤関連深部静脈血栓症の大規模薬剤疫学解析

対象DB：FAERS

30. Real-World Evidence Evaluation of Respiratory Syncytial Virus (RSV) Vaccines: Deep Dive into Vaccine Adverse Events Reporting System.

RSVワクチンの市販後安全性評価

対象DB：FAERS,VAERS

31. Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system.

ROS1阻害薬の神経系有害事象解析

対象DB：FAERS

32. Atrial fibrillation signals associated with overactive bladder drugs across JADER and FAERS: disproportionality and time-to-onset analyses.

過活動膀胱薬と心房細動の薬剤疫学解析

対象DB：FAERS,JADER

33. Signals of interstitial lung disease with novel antineoplastic agents in ovarian cancer: a three-database disproportionality study.

卵巣がん新規抗腫瘍薬とILDリスク解析

対象DB：CVAR,FAERS,JADER

34. Gender and age variations in neuropsychiatric adverse events of cetirizine and levocetirizine: a disproportionality analysis of ICSRs from FAERS and EudraVigilance data.

セチリジン系抗ヒスタミン薬の神経精神リスク解析

対象DB：EudraVigilance,FAERS

35. Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024.

FAERSで末梢神経麻痺高リスク薬を同定

対象DB：FAERS

36. Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance.

バリシチニブのCKD機序と安全性統合解析

対象DB：FAERS

37. A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.

テポチニブ腎障害の分子安全性評価

対象DB：FAERS

38. Understanding Senna Risks: Evidence from the FDA Adverse Event Reporting System.

センナ使用に伴う有害事象の実態解析

対象DB：FAERS

39. Urinary Tract Infections and Fungal Infections Associated with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors and Metformin Combination: A Real-World Study from 2013 to 2023 Based on the FDA Adverse Event Reporting System (FAERS) Database.

SGLT2阻害薬と尿路・真菌感染リスク比較

対象DB：FAERS

40. Resistance, Ineffectiveness, and Off-Label Use Related to Cephalosporins from the Reserve Group-A Pharmacovigilance Signal Detection Study on EudraVigilance Database.

リザーブ系セファロスポリン耐性・無効性シグナル解析

対象DB：EudraVigilance

41. Divergent System Organ Class Safety Profiles of Isotretinoin Versus Topical Retinoids: An EudraVigilance Disproportionality Analysis.

イソトレチノインの安全性比較解析

対象DB：EudraVigilance

42. Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries.

CML治療TKIの肺毒性リスク比較（欧州EV）

対象DB：EudraVigilance

43. Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system.

オラパリブ関連薬剤性肝障害の実態解析

対象DB：EudraVigilance

44. VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines.

VigiBaseの概要と世界的薬剤安全性監視データベース

対象DB：VigiBase

45. Cytopenias as Adverse Drug Reactions: A 10-Year Analysis of Reporting Structure, Rate, and Trend.

薬剤性血球減少症の世界・セルビア報告動向分析

対象DB：VigiBase

46. Correlation Between the Dementia Assessment Sheet for Community-Based Integrated Care System-21 Scores and Criteria for Determination of the Daily Life Independence Level of Older Adults With Dementia Using the Diagnosis Procedure Combination Database.

DPCデータにおける認知症自立度基準の妥当性検証

対象DB：DPC

47. Clinical Outcomes of Dantrolene in Neuroleptic Malignant Syndrome: A Nationwide Retrospective Study.

悪性症候群に対する早期ダントロレン投与と予後

対象DB：DPC

48. Nationwide field evaluation of early oral intake following gastric cancer surgery.

胃癌手術後の早期経口摂取の実施状況と施設要因

対象DB：DPC

49. Outcomes of combined carbazochrome sodium sulfonate plus tranexamic acid therapy versus tranexamic acid monotherapy in traumatic brain injury: a retrospective cohort study in Japan.

外傷性脳損傷へのCSS・TXA併用はTXA単独と予後に差なし。

対象DB：DPC

50. Validation of the Diagnosis Procedure Combination Database in Japan for ICU Research: A Multicenter Comparison with the Japanese Intensive care PAtient Database (JIPAD).

日本のDPCデータがICU研究の指標を正確に捉えることを検証。

対象DB：DPC

51. Assessing ethnic inequalities in diagnostic intervals of breast cancer among patients presenting symptoms to general practitioners in England.

イングランドの乳がん診断期間における民族間の格差を調査。

対象DB：CPRD

52. Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease.

臨床試験外の患者背景に基づき、アスピリン予防の妥当性を評価。

対象DB：CPRD

53. A multidimensional framework for mapping social need to electronic health records in people with multimorbidity.

多疾患併存患者の社会的ニーズを特定する新たな枠組みを提示。

対象DB：CPRD

54. Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout.

痛風治療で目標尿酸値を達成すると心血管リスクが低下する可能性。

対象DB：CPRD

55. Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.

多発性骨髄腫患者は診断前から骨折リスクが高く、対策が重要。

対象DB：CPRD

56. Academic impact and research data utilisation of the clinical practice research datalink: scientometric analyses.

英CPRDデータの学術的インパクトと利用動向を計量分析。

対象DB：CPRD

57. Risk of hospitalization and death among autistic young people in England during the Covid-19 pandemic.

自閉症者はパンデミック下で入院・死亡リスクが高いことを示唆。

対象DB：CPRD

58. A Retrospective Analysis of the Clinical Characteristics and Treatment Patterns Among Individuals with Diabetes Receiving Insulin Therapy in Japan: The Insulin JP2DB Study.

日本の糖尿病患者のインスリン開始時のレジメンと推移を解析。

対象DB：DeSC